Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.23.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents [note 6] $ 16,514 $ 24,771
Grant receivable [note 3] 89 105
Prepaid expenses and other assets 1,621 2,454
Total current assets 18,224 27,330
Right-of-use assets [note 9] 109 66
Other assets and restricted cash [note 6] 68 123
License agreement [note 4 and note 5] 1,363 1,418
Goodwill [note 5] 1,034 1,034
Total assets 20,798 29,971
Current liabilities:    
Accounts payable 1,063 1,660
Accrued liabilities other 699 403
Accrued clinical liabilities 1,363 1,729
Accrued compensation 747 1,678
Current portion of long-term obligations [note 9] 58 58
Convertible debt [note 6 and note 7] 16,371 16,071
Total current liabilities 20,301 21,599
Long-term obligations [note 9] 54 69
Total liabilities 20,355 21,668
Commitments and contingencies [note 9]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 17,930,362 issued and outstanding at March 31, 2023 and 17,897,029 issued and outstanding at December 31, 2022 87 87
Additional paid-in capital 145,280 144,148
Accumulated deficit (144,928) (135,936)
Accumulated other comprehensive income 4 4
Total stockholders' equity 443 8,303
Total liabilities and stockholders' equity 20,798 29,971
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value